BNP Paribas Financial Markets Purchases 17,533 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

BNP Paribas Financial Markets boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 602.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,441 shares of the biotechnology company’s stock after purchasing an additional 17,533 shares during the period. BNP Paribas Financial Markets’ holdings in REGENXBIO were worth $214,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Integral Health Asset Management LLC grew its stake in shares of REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after buying an additional 190,000 shares during the last quarter. Quest Partners LLC grew its position in REGENXBIO by 11,731.0% in the 2nd quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock valued at $491,000 after acquiring an additional 41,645 shares during the last quarter. Squarepoint Ops LLC increased its stake in REGENXBIO by 630.9% in the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock worth $1,711,000 after purchasing an additional 126,249 shares during the period. Acadian Asset Management LLC bought a new stake in shares of REGENXBIO during the second quarter worth $494,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after purchasing an additional 37,055 shares during the period. 88.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on RGNX shares. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price target on shares of REGENXBIO in a research note on Wednesday, December 11th. Finally, HC Wainwright lowered their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.27.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now owns 11,286 shares in the company, valued at $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 13.13% of the company’s stock.

REGENXBIO Stock Up 3.1 %

Shares of REGENXBIO stock opened at $8.54 on Tuesday. REGENXBIO Inc. has a 52-week low of $8.06 and a 52-week high of $28.80. The firm’s 50 day moving average price is $9.72 and its 200-day moving average price is $11.33. The company has a market cap of $423.11 million, a P/E ratio of -1.70 and a beta of 1.24.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.